Back to Browse Journals » Biologics: Targets and Therapy » Volume 2 » Issue 4

Denileukin diftitox for the treatment of cutaneous T-cell lymphoma

Authors David Kaminetzky, Kenneth B Hymes

Published 5 December 2008 Volume 2008:2(4) Pages 717—724

DOI https://doi.org/10.2147/BTT.S3084

Review by Single-blind

Peer reviewer comments 3

David Kaminetzky1, Kenneth B Hymes2

1Division of Hematology/Oncology, New York University School of Medicine, New York, USA; 2New York University Cancer Institute, New York, USA

Abstract: Cutaneous T-cell lymphoma/mycosis fungoides (CTCL/MF) is a rare lymphoproliferative disorder which can present as an indolent or as an aggressive process involving skin, lymph nodes, and blood. In stages IA, IB and IIA, it is usually managed with topical medications and phototherapy. If there is progression despite application of these treatments, or if the patient presents with a higher stage of disease, systemic chemotherapy or retinoids, rexinoids, biologic response modifiers are often necessary. Consequently, patients are often treated with a sequence of modalities and drugs. Denileukin diftitox (DD, Ontak®) is a targeted immunotoxin which has biological activity against malignancies expressing the IL-2 receptor. In addition to its unique mechanism of action, DD has a toxicity profile which does not overlap with most commonly used chemotherapeutic agents. CTCL/MF has been found be particularly susceptible to treatment with this agent. This review will describe the development DD, its proposed mechanism of action, the clinical trials which identified its utility in the treatment of CTCL/MF, the common toxicities encountered with this agent, and the management of these toxicities. In addition the incorporation of DD in the sequential treatment of CTCL/MF and data suggesting potential combination therapies employing this novel agent will be discussed.

Keywords: T-cell lymphoma, mycosis fungoides, immunotoxin, cytokine therapy, denileukin diftitiox

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus

Omoto S, Taniura T, Nishizawa T, Tamaki T, Shouzu A,Nomura S

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2015, 8:339-345

Published Date: 27 July 2015

The clinicopathological significance of CDH1 in gastric cancer: a meta-analysis and systematic review

Zeng W, Zhu J, Shan L, Han Z, Aerxiding P, Quhai A, Zeng F, Wang Z, Li H

Drug Design, Development and Therapy 2015, 9:2149-2157

Published Date: 13 April 2015

Enhancement of radiotherapy efficacy by miR-200c-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer cells

Cui FB, Liu Q, Li RT, Shen J, Wu PY, Yu LX, Hu WJ, Wu FL, Jiang CP, Yue GF, Qian XP, Jiang XQ, Liu BR

International Journal of Nanomedicine 2014, 9:2345-2358

Published Date: 13 May 2014

Corrigendum

Wu Q, Chu M

International Journal of Nanomedicine 2012, 7:4531-4532

Published Date: 15 August 2012

Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles

Wang W, Zhu R, Xie Q, Li A, Xiao Y, Liu H, Cui D, Chen Y, Wang S

International Journal of Nanomedicine 2012, 7:3667-3677

Published Date: 17 July 2012

Targeted therapies in the management of metastatic bladder cancer

Matteo Fassan, Edouard J Trabulsi, Leonard G Gomella, Raffaele Baffa

Biologics: Targets and Therapy 2007, 1:393-406

Published Date: 15 February 2008